Linked Data API

Show Search Form

Search Results

692586
star this property registered interest false more like this
star this property date less than 2017-02-21more like thismore than 2017-02-21
star this property answering body
Home Office more like this
star this property answering dept id 1 more like this
star this property answering dept short name Home Office more like this
star this property answering dept sort name Home Office more like this
star this property hansard heading Cannabis: Research more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for the Home Department, with reference to the oral contribution of the then Minister for Policing, Crime and Criminal Justice on 20 January 2016, Official Report, column 1479, what progress her Department has made on the use of cannabis for the purposes of medicinal research. more like this
unstar this property tabling member constituency Central Suffolk and North Ipswich more like this
star this property tabling member printed
Dr Poulter more like this
star this property uin 64923 remove filter
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-02-27more like thismore than 2017-02-27
star this property answer text <p>Access to controlled drugs for legitimate medicinal (or exceptionally for industrial purposes) is permitted through the Misuse of Drugs Regulations 2001.</p><p> </p><p>There is a clear regime in place, administered by the Medicines and Healthcare products Regulatory Agency (MHRA), to enable medicines (including those containing controlled drugs such as cannabis) to be developed, licensed and made available for medicinal use to patients in the UK. For example, the cannabis-based medicine ‘sativex’ has been granted Marketing Authorisation in the UK by the MHRA for the treatment of spasticity due to multiple sclerosis. Sativex was rigorously tested for its safety and efficacy before receiving approval for this application.</p><p> </p><p>The MHRA is open to considering marketing approval applications for other medicinal cannabis products should a product be developed. As happened in the case of sativex, the Home Office will consider issuing a licence to enable trials of any new medicine providing it complies with appropriate ethical approvals.</p>
star this property answering member constituency Truro and Falmouth remove filter
star this property answering member printed Sarah Newton more like this
star this property question first answered
less than 2017-02-27T14:40:40.427Zmore like thismore than 2017-02-27T14:40:40.427Z
star this property answering member
4071
star this property label Biography information for Sarah Newton more like this
star this property tabling member
3932
star this property label Biography information for Dr Dan Poulter more like this